Molecular diagnostics firm Myriad Genetics has introduced its EndoPredict test in the US for patients with ER+ HER2- early-stage breast cancer.
EndoPredict is a second-generation, multigene test designed to predict the ten year risk of disease recurrence after surgery and determine the patients who can safely drop adjuvant chemotherapy.
The test provides information to establish personalised treatment plans for the patients.
Myriad Genetic Laboratories chief medical officer Johnathan Lancaster said: "Breast cancer is a complicated disease and there is a critical need for accurate breast cancer recurrence tests that help physicians determine which patients can safely forgo adjuvant chemotherapy.
"By automatically incorporating clinical features and generating an individualised patient test result, EndoPredict identifies a larger subset of true low-risk patients who may safely forgo adjuvant chemotherapy."
EndoPredict showed positive outcome in several prospective clinical trials conducted in more than 3,500 patients with ER+ HER2- node negative and node positive early-stage breast cancer.
The results from the clinical development programme indicated that EndoPredict performs better than the first generation breast cancer recurrence tests.
Using 10-year outcomes data that includes proliferation-related genes and hormone receptor-related genes, EndoPredict was trained and validated to provide precise assessment of early and late risk for recurrence as well as to determine low or high-risk patients.
The test has been clinically used in more than 13,000 patients.
Myriad discovers and commercialises molecular diagnostic tests to determine the risk of developing disease, diagnose disease, assess the risk of disease progression and guide treatment decisions.
Image: Testing in a lab. Photo: courtesy of Myriad Genetics.